whether
care
individu
patient
infecti
diseas
respond
worldwid
pandem
rapid
accur
establish
microbi
caus
fundament
qualiti
care
despit
dramat
advanc
diagnost
technolog
mani
patient
suspect
infect
receiv
empir
antimicrobi
therapi
rather
appropri
therapi
dictat
rapid
identif
infecti
agent
result
overus
small
inventori
effect
antimicrobi
whose
number
continu
dwindl
due
increas
level
antimicrobi
resist
new
test
need
identifi
specif
pathogen
minimum
distinguish
bacteri
viral
infect
also
provid
inform
suscept
antimicrobi
agent
test
easi
use
provid
rapid
result
ideal
within
hour
posit
impact
care
result
must
effect
commun
healthcar
provid
public
health
practition
may
requir
interpret
expertis
infecti
diseas
physician
clinic
microbiologist
infecti
diseas
physician
serv
bridg
laboratori
healthcar
provid
ensur
proper
use
interpret
diagnost
test
expertis
infecti
diseas
clinician
becom
import
advent
newer
complex
test
avail
need
test
lead
improv
clinic
outcom
patient
antimicrobi
stewardship
detect
track
diseas
outbreak
investig
unknown
pathogen
unit
state
global
emerg
technolog
enabl
detect
quantif
pathogen
burden
new
speed
sensit
simplic
use
howev
signific
challeng
develop
regulatori
approv
clinic
integr
diagnost
test
use
new
technolog
need
diagnost
advanc
clinic
care
public
health
never
greater
critic
window
opportun
har
new
technolog
address
greatest
unmet
need
infecti
diseas
societi
america
idsa
polici
paper
review
current
diagnost
landscap
includ
unmet
need
emerg
technolog
assess
challeng
develop
clinic
integr
improv
test
fulfil
promis
emerg
diagnost
idsa
present
recommend
address
host
identifi
barrier
achiev
goal
requir
engag
coordin
number
stakehold
includ
congress
fund
regulatori
bodi
public
health
agenc
diagnost
industri
healthcar
system
profession
societi
individu
clinician
gram
stain
still
often
first
line
diagnosi
infecti
diseas
consult
microscopi
without
stain
permit
diagnosi
mani
infecti
diseas
exampl
acut
gonococc
urethr
primari
syphili
differenti
gramposit
gramneg
pathogen
sputum
smear
detect
mycobacterium
tuberculosi
similar
pathogen
monoclon
antibodi
tag
fluorescein
enabl
microbiologist
visual
organ
legionella
pneumophila
stain
well
convent
stain
enhanc
detect
pathogen
tuberculosi
pneumocysti
jirovecii
evolv
bacteri
cultur
method
eventu
viral
tissu
cultur
amplifi
abil
detect
specif
pathogen
enabl
recoveri
pathogen
pure
cultur
allow
suscept
test
bacteria
specif
antimicrobi
agent
howev
major
disadvantag
culturebas
method
time
need
cultur
growth
tabl
provid
snapshot
time
requir
pathogen
identif
use
variou
diagnost
method
develop
biochemistri
enabl
detect
specif
metabol
product
exampl
time
requir
detect
identif
slowgrow
tuberculosi
substanti
reduc
radiometr
detect
carbon
dioxid
produc
metabol
palmit
acid
antibodi
detect
enzym
immunoassay
eia
enzymelink
immunosorb
assay
enhanc
use
analyt
detector
spectrophotomet
fluoromet
luminomet
radioact
counter
specif
antigen
antibodi
detect
increas
use
monoclon
antibodi
recombin
antigen
modern
antibodi
panel
detect
multipl
antigen
andor
antibodi
presenc
igm
iga
antibodi
within
hour
specimen
submiss
exampl
antigen
detect
specif
antibodi
includ
rapid
test
streptococcu
pyogen
throat
cryptococc
antigen
blood
csf
detect
antigen
streptococcu
pneumonia
legionella
pneumophila
serogroup
histoplasma
capsulatum
urin
assay
rapid
culturebas
test
requir
cultiv
viabl
organ
howev
increas
sensit
cultur
provid
inform
suscept
microorgan
antimicrobi
drug
last
decad
wit
develop
polymeras
chain
reaction
pcr
nucleic
amplif
technolog
naat
detect
microbi
host
genet
sequenc
great
sensit
specif
nucleic
acid
amplif
method
increasingli
employ
detect
often
quantit
everincreas
number
pathogen
exampl
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
cytomegaloviru
cmv
bk
viru
use
molecular
diagnost
quantifi
hiv
type
hbv
hcv
revolution
develop
antiretrovir
drug
could
util
manag
treatment
viral
infect
begin
signific
transform
diagnost
critic
capit
current
opportun
invest
need
diagnost
enabl
util
improv
diagnost
clinic
manag
public
health
surveil
primari
role
diagnost
identifi
diseas
enabl
manag
individu
patient
nucleic
technolog
enhanc
diagnosi
bacteri
viral
infect
result
increas
test
sensit
rapid
turnaround
time
addit
knowledg
sequenc
underli
drug
resist
allow
detect
microorgan
carri
drug
resist
gene
exampl
earli
detect
infect
strain
resist
select
antiretrovir
drug
enabl
physician
around
world
accur
diagnos
treat
infect
appropri
antiretrovir
newer
autom
test
use
nanotechnolog
longer
requir
addit
multipl
reagent
use
pointofcar
diagnosi
number
commerci
avail
test
use
continu
increas
logarithm
cost
instrument
assay
continu
decreas
last
year
fda
clear
k
pathway
approv
premarket
approv
pathway
numer
molecular
diagnost
test
tabl
nucleic
acid
amplif
method
viral
target
whole
faster
sensit
costeffect
tradit
cultur
method
diagnosi
enterovir
mening
herp
simplex
viru
hsv
enceph
cmv
infect
immunocompromis
patient
exampl
clinic
relev
costeffect
applic
nucleic
test
convent
method
readili
replac
virolog
bacteriolog
tissu
virolog
method
costli
gener
less
sensit
newer
molecular
method
virus
highli
labil
eg
respiratori
syncyti
viru
rsv
routin
cultur
eg
coronavirus
danger
cultur
eg
variola
antivir
suscept
test
routin
perform
need
identif
ganciclovirresist
cmv
mutat
rapidli
identifi
use
nucleic
acid
amplif
coupl
sequenc
addit
fdaclear
multiplex
assay
util
realtim
amplif
method
enabl
simultan
detect
multipl
respiratori
virus
research
assay
detect
nucleic
acid
virus
heretofor
unrecogn
andor
cultivat
vitro
beyond
pathogen
identif
molecular
method
guid
patient
manag
quantif
viral
nucleic
acid
use
stage
diseas
activ
prognost
diseas
progress
monitor
efficaci
therapi
exampl
risk
progress
aid
ultim
death
directli
relat
magnitud
rna
level
plasma
similarli
viral
load
determin
risk
perinat
sexual
transmiss
reduct
viral
load
level
associ
increas
patient
surviv
decreas
viral
transmiss
genotyp
select
pathogen
import
specif
therapeut
protocol
especi
hcv
antivir
suscept
test
also
guid
specif
therapi
genotyp
molecular
method
also
prognost
valu
exampl
human
papillomaviru
hpv
type
associ
highrisk
progress
neoplasia
type
associ
vener
wart
low
risk
neoplasia
test
highrisk
hpv
dna
establish
method
manag
women
cervic
cytolog
diagnosi
atyp
squamou
cell
undetermin
signific
patient
refer
colposcopi
base
detect
highrisk
type
hpv
dna
similarli
cmv
load
test
help
distinguish
activ
diseas
asymptomat
infect
higher
level
cmv
dna
increas
risk
activ
diseas
thu
cmv
load
measur
use
decid
initi
preemptiv
therapi
organ
transplant
recipi
like
quantit
assay
also
help
distinguish
diseas
asymptomat
infect
herpesvirus
epsteinbarr
viru
human
herpesviru
molecular
method
particularli
signific
impact
discoveri
previous
unrecogn
uncultiv
pathogen
hcv
tropheryma
whipplei
exampl
uncultiv
microorgan
first
detect
molecular
method
nucleotid
sequenc
analysi
bacteri
rna
gene
expand
knowledg
phylogenet
relationship
among
bacteria
frequent
use
bacteri
identif
assess
nosocomi
commun
outbreak
epidemiolog
surveil
pyrosequenc
ultradeep
sequenc
enabl
detect
multipl
strain
within
singl
individu
identif
minor
mutant
quasispeci
similarli
pyrosequenc
use
classifi
mycobacteria
nocardia
clinic
import
group
identifi
yeast
filament
fungi
infecti
diseas
close
depend
natur
complex
human
behavior
reflect
interact
peopl
anim
environ
recent
chang
global
climat
environment
chang
hurrican
flood
earthquak
dramat
influenc
frequenc
certain
diseas
new
locat
postearthquak
cholera
haiti
expans
dengu
north
america
dysenteri
pakistan
flood
minut
dramat
chang
environ
signific
impact
spread
mosquito
diseas
vector
result
resurg
diseas
malaria
dengu
diagnost
critic
tool
keep
continu
chang
diseas
dynam
mani
applic
beyond
individu
patient
manag
use
infecti
diseas
diagnost
includ
epidemiolog
surveil
infect
control
effort
antimicrobi
stewardship
facilit
clinic
trial
enrol
companion
diagnost
codevelop
drug
diagnost
test
case
epidemiolog
surveil
genet
detect
rifampin
resist
tuberculosi
use
marker
multidrug
resist
enabl
public
health
offici
estim
extent
diseas
within
select
popul
optim
antimycobacteri
therapi
antimicrobi
stewardship
optim
antimicrobi
use
clinic
set
enhanc
assay
detect
antimicrobi
resist
gene
exampl
molecular
assay
detect
presenc
methicillin
resist
gene
staphylococcu
aureu
isol
extendedspectrum
carbapenemas
resist
gene
gramneg
bacilli
surveil
penicillinaseproduc
andor
fluoroquinoloneresist
neisseria
gonorrhoea
achiev
new
assay
pulsedfield
gel
electrophoresi
repetit
pcr
reppcr
increasingli
whole
genom
sequenc
use
character
outbreak
diseas
multipl
healthcar
set
new
gener
antimicrobi
antivir
agent
highlight
need
diagnost
test
identifi
subpopul
patient
benefit
therapi
classic
exampl
detect
tropism
use
antiretrovir
drug
maraviroc
competit
bind
cell
presenc
tropic
viru
strain
dramat
lower
effect
drug
henc
use
maraviroc
entri
inhibitor
encourag
fda
individu
identifi
hiv
tropism
fdaclear
multiplex
pcr
platform
design
probe
respiratori
specimen
stool
sampl
posit
blood
cultur
bottl
array
pertin
pathogen
mani
test
classifi
moder
complex
waiv
clia
regul
addit
fda
approv
clearanc
new
diagnost
test
cm
regul
conduct
diagnost
test
unit
state
clia
test
categor
accord
complex
differ
requir
personnel
expertis
document
oversight
simpl
lowrisk
test
waiv
perform
physician
offic
locat
without
routin
regulatori
oversight
appropri
train
waiv
moder
complex
test
perform
laboratori
assist
healthcar
personnel
nurs
clinic
personnel
instrument
locat
outsid
central
laboratori
eg
rapid
respons
laboratori
adjac
emerg
room
larg
physician
offic
build
result
avail
within
hour
henc
inform
critic
patient
manag
decis
exampl
whether
initi
antivir
therapi
influenza
begin
therapi
tuberculosi
initi
antibiot
prophylaxi
pregnant
women
carriag
group
b
streptococci
whether
higher
level
care
ie
outpati
inpati
set
may
appropri
wherea
signific
recent
advanc
field
clinic
microbiolog
increas
avail
molecular
diagnost
test
test
still
optim
integr
clinic
care
benefit
patient
avail
test
address
prioriti
clinic
need
healthcar
provid
inadequ
inform
avail
util
mani
test
barrier
research
develop
regulatori
approv
need
diagnost
challeng
laboratori
adopt
integr
diagnost
divers
healthcar
set
rest
paper
investig
question
offer
recommend
address
identifi
challeng
patient
outpati
clinic
set
often
serious
ill
may
infect
would
benefit
antimicrobi
therapi
overus
antibiot
howev
signific
problem
among
outpati
exampl
sever
studi
document
adult
pediatr
outpati
present
acut
upper
respiratori
tract
infect
receiv
antibiot
despit
fact
major
ill
caus
virus
antibiot
prescrib
situat
partli
due
inabl
exclud
bacteri
infect
identifi
viral
pathogen
quickli
unmet
diagnost
need
outpati
clinic
thu
includ
develop
test
accur
rule
bacteri
infect
eg
biomark
distinguish
viral
vs
bacteri
pneumonia
suffici
certainti
antibiot
avoid
applic
poc
test
reliabl
detect
viral
andor
bacteri
pathogen
would
result
enhanc
care
less
antibiot
empiric
least
theori
reduc
patient
societ
cost
ill
accur
test
detect
infect
singl
common
pathogen
influenza
use
direct
downstream
patient
manag
also
use
outpati
set
pediatr
studi
particular
shown
decreas
use
antibiot
increas
use
antivir
influenza
diagnos
rapid
test
similar
result
shown
group
streptococcu
unfortun
wide
util
poc
diagnost
rapid
antigen
test
often
limit
sensit
impact
clinic
manag
decis
test
result
need
within
roughli
hour
short
time
frame
would
met
cliawaiv
test
perform
physician
medic
assist
immedi
contigu
rapid
respons
laboratori
test
current
avail
meet
criteria
fulli
autom
molecular
technolog
high
sensit
specif
eg
respiratori
tract
infect
current
either
expens
time
consum
andor
low
enough
complex
routin
use
clinic
anticip
howev
price
fulli
autom
molecular
platform
decreas
result
manufactur
advanc
free
market
competit
physician
emerg
depart
ed
face
mani
issu
outpati
physician
work
within
differ
framework
differ
set
resourc
dispos
ed
physician
often
manag
patient
sicker
ongo
relationship
mean
followup
infecti
diseas
decis
make
ed
revolv
around
empir
antimicrobi
prescrib
extent
test
whether
patient
ill
requir
care
gener
hospit
bed
icu
diagnosi
manag
communityacquir
pneumonia
cap
illustr
need
rapid
result
ie
test
result
avail
clinician
ed
encount
test
high
enough
prognost
valu
allow
safe
outpati
discharg
versu
hospit
admiss
microbiolog
test
etiolog
diagnosi
cap
present
controversi
idsaamerican
thorac
societi
at
guidelin
time
literatur
indic
low
diagnost
yield
tradit
cultur
sensit
henc
minim
impact
clinic
care
idsaat
recommend
call
improv
diagnost
capabl
symptom
bacteri
cap
overlap
viral
caus
pneumonia
well
exacerb
asthma
chronic
obstruct
pulmonari
diseas
addit
medicar
perform
measur
requir
appropri
empir
therapi
select
cap
ed
fda
clearanc
compet
multiplex
platform
signal
dramat
increas
power
detect
pathogen
airway
panel
contain
viral
analyt
bacteri
analyt
prospect
reduc
empir
antibiot
use
evolv
rapidli
literatur
last
sever
decad
indic
identif
etiolog
cap
patient
least
scandinavian
studi
use
modern
method
increas
percentag
problem
current
panel
detect
atyp
bacteria
eg
mycoplasma
pneumonia
chlamydophila
pneumonia
typic
bacteri
pathogen
haemophilu
influenza
pneumonia
challeng
typic
bacteria
viral
pathogen
need
determin
identifi
pathogen
colon
invad
henc
increas
interest
biomark
procalcitonin
pct
promis
biomark
use
addit
fever
leukocytosi
clinic
syndrom
predictor
bacteri
infect
oppos
outpati
clinic
set
ed
associ
inpati
facil
therefor
diagnost
test
order
ed
complex
necessarili
requir
clia
waiver
meet
need
rapid
turnaround
time
mani
hospit
develop
rapidrespons
section
within
clinic
laboratori
locat
near
patient
staf
select
test
hour
day
day
week
laboratori
structur
perform
fulli
autom
molecular
test
andor
pct
test
addit
mani
ed
adopt
cliawaiv
pct
test
urin
dipstick
test
pregnanc
test
perform
ancillari
staff
ed
time
patient
visit
turnaround
time
critic
test
conduct
ed
use
make
prescrib
decis
patient
ultim
discharg
determin
need
higher
level
care
icu
admiss
contact
respiratori
isol
diagnost
test
ideal
provid
result
within
hour
diagnosi
meningoenceph
challeng
differenti
diagnosi
often
extens
includ
infecti
postinfecti
noninfecti
caus
addit
routin
cultur
method
slow
recoveri
viabl
microb
may
diminish
prior
receipt
antibiot
sensit
molecularbas
assay
detect
viral
pathogen
directli
csf
develop
current
fdaclear
test
enterovirus
potenti
benefit
rapid
naat
perhap
best
exemplifi
clinic
studi
hsv
enceph
adult
enteroviru
mening
children
pcr
test
csf
sensit
brain
biopsi
diagnosi
hsv
enceph
time
access
enteroviru
revers
transcript
pcr
rtpcr
result
facilit
shorter
hospit
stay
reduc
antibiot
use
lessen
ancillari
laboratori
test
despit
comprehens
evalu
varieti
differ
laboratori
test
includ
serolog
culturebas
method
current
avail
molecular
assay
mani
patient
enceph
remain
undiagnos
new
test
diagnosi
acut
chronic
cn
infect
clearli
need
given
breadth
pathogen
implic
cn
diseas
comprehens
molecular
panel
agent
meningoenceph
immunocompet
well
immunocompromis
host
would
bring
ad
valu
commerci
avail
test
addit
impact
assay
patient
outcom
overal
cost
hospit
care
requir
justifi
routin
use
acut
organ
dysfunct
secondari
infect
medic
emerg
increas
incid
like
enceph
diagnosi
sepsi
may
difficult
clinic
sign
overlap
noninfecti
caus
system
inflamm
blood
cultur
result
typic
requir
day
complet
earli
fluid
resuscit
combin
initi
appropri
antimicrobi
therapi
improv
outcom
clinic
paramet
heart
sepsi
definit
ie
system
inflammatori
respons
syndrom
sir
lack
specif
toward
etiolog
diagnosi
consequ
approxim
patient
sever
sepsi
receiv
inadequ
empir
antimicrobi
therapi
hand
indiscrimin
use
multipl
antibiot
may
detriment
effect
advers
event
c
difficil
infect
rise
antimicrobi
resist
procalcitonin
wide
studi
surrog
marker
bacteri
infect
patient
sir
pct
level
increas
varieti
shock
exampl
bacterem
shock
cardiogen
shock
neurogen
shock
condit
caus
low
flow
state
perhap
allow
transloc
gut
bacteria
hand
prefer
normal
pct
level
hypotens
patient
virtual
elimin
invas
bacteri
infect
etiolog
neg
predict
valu
sequenti
pct
level
excel
guid
durat
antibacteri
therapi
better
understand
pct
function
within
broader
innat
immun
respons
correl
microbi
etiolog
still
need
furthermor
highli
sensit
test
ie
neg
predict
valu
would
requir
confid
withhold
broadspectrum
antibiot
critic
ill
patient
system
sign
infect
research
ongo
identifi
new
biomark
combin
marker
distinguish
sir
relat
infect
addit
host
gene
express
profil
use
peripher
blood
mononuclear
cell
suggest
distinct
biosignatur
use
differenti
gramposit
gramneg
infect
well
viral
bacteri
fungal
process
proteom
pattern
similarli
assess
diagnost
potenti
challeng
conduct
clinic
studi
identifi
valid
diagnost
andor
prognost
signatur
ultim
pathogenspecif
test
need
guid
antimicrobi
manag
septic
patient
fdaclear
multiplex
pcr
panel
avail
identifi
small
number
microorgan
posit
blood
cultur
bottl
within
hour
oppos
sever
day
usual
requir
molecular
diagnost
detect
microbi
dna
directli
blood
achiev
modest
level
success
sever
limit
still
exist
studi
panbacteri
pcr
exampl
confound
presenc
pathogen
dna
contamin
introduc
time
specimen
collect
andor
prepar
turnaround
time
result
lengthen
need
dna
sequenc
follow
nucleic
acid
amplif
multiplex
pcr
panel
design
directli
detect
identifi
common
bacteri
fungal
caus
bloodstream
infect
within
sever
hour
develop
posit
agreement
commerci
pcr
blood
cultur
rang
nonneutropen
patient
illustr
current
molecular
assay
remain
rel
insensit
compar
blood
cultur
furthermor
clinic
signific
specimen
posit
pcr
neg
cultur
organ
bodi
site
remain
difficult
interpret
standard
naat
test
differenti
viabl
nonviabl
organ
multicent
clinic
trial
necessari
defin
diagnost
accuraci
molecular
assay
perform
blood
sensit
approach
obvious
need
base
avail
data
welldesign
multiplex
pcr
appear
valu
sepsi
diagnost
use
conjunct
convent
cultur
routin
antibiot
suscept
test
look
forward
diagnost
strategi
incorpor
sensit
biomark
eg
infect
present
yesno
follow
pathogenspecif
test
link
rapid
assess
drug
resist
could
revolution
sepsi
manag
time
report
key
drug
resist
determin
meca
gene
associ
aureu
methicillin
resist
blakpc
carbapenemas
harbor
klebsiella
pneumonia
escherichia
coli
isol
essenti
optimum
impact
antimicrobi
select
infect
control
practic
backup
vitro
suscept
test
would
still
necessari
verifi
resist
gene
function
healthcareassoci
pneumonia
hcap
includ
hospitalacquir
pneumonia
hap
ventilatorassoci
pneumonia
vap
common
healthcareassoci
infect
manifest
high
morbid
mortal
hcap
hap
vap
caus
wide
varieti
mostli
bacteri
pathogen
may
polymicrobi
frequenc
specif
multidrugresist
pathogen
like
vari
across
institut
differ
patient
popul
thu
emphas
need
local
surveil
data
current
hcap
guidelin
recommend
immedi
empir
therapi
treatment
delay
affect
mortal
definit
diagnosi
difficult
approach
like
lead
overtreat
mani
noninfecti
process
mimic
pneumonia
altern
manag
strategi
predic
microbiolog
associ
less
antibiot
usag
icu
patient
potenti
improv
patient
outcom
lower
respiratori
tract
specimen
eg
tracheal
aspir
bronchoalveolar
lavag
protect
brush
prefer
make
microbiolog
diagnosi
hap
vap
invas
sampl
may
alway
possibl
furthermor
posit
gram
stain
cultur
lower
respiratori
tract
alway
distinguish
invas
pathogen
airway
colon
quantit
cultur
lower
respiratori
tract
specimen
advoc
improv
diagnost
specif
howev
recent
cochran
review
conclud
quantit
improv
outcom
intub
patient
compar
manag
qualit
result
respiratori
specimen
amen
rapid
molecular
test
yet
current
commerci
avail
pathogenspecif
assay
hap
vap
although
offlabel
studi
shown
success
detect
aureu
infect
like
sepsi
futur
assay
develop
also
includ
simultan
assess
key
drug
resist
gene
separ
commens
asymptomat
colon
overt
pathogen
patient
fever
leukocytosi
pulmonari
infiltr
quantit
molecular
result
may
prove
use
unlik
quantit
cultur
addit
novel
approach
detect
specif
virul
determin
need
hospit
epidemiologist
infect
preventionist
deal
issu
rang
isol
patient
transmiss
infect
outbreak
investig
unmet
diagnost
need
arena
primarili
relat
rapid
identif
hospit
patient
contagi
ill
drugresist
pathogen
rapid
type
organ
determin
epidemiolog
linkag
rapid
identif
antibiot
resist
central
time
isol
patient
harbor
drugresist
organ
rapid
test
fda
clear
methicillinresist
staphylococcu
aureu
mrsa
screen
vanacontain
vancomycinresist
enterococci
vre
new
assay
avail
rapid
detect
mrsa
vre
posit
blood
cultur
bottl
gramneg
resist
highli
complex
test
identifi
organ
produc
extendedspectrum
carbapenemas
recent
avail
horizon
recent
issu
hospit
epidemiolog
infect
control
one
particularli
promin
pediatr
isol
patient
test
posit
respiratori
pathogen
pcr
increas
sensit
pcr
introduct
larg
pathogen
panel
significantli
increas
number
hospit
patient
respiratori
isol
necessari
particularli
case
rhinoviru
shed
prolong
detect
common
among
healthi
person
understand
children
requir
isol
import
unansw
question
addit
determin
whether
pcrbase
detect
indic
activ
infect
transmiss
postexposur
prophylaxi
necessari
pathogen
primari
dual
detect
import
clinic
cohort
purpos
bordetella
pertussi
detect
pcr
rais
issu
recent
outbreak
highlight
need
solut
quantit
pcr
may
help
regard
need
addit
studi
prompt
outbreak
identif
central
control
spread
diseas
recogn
outbreak
occur
difficult
type
method
detect
organ
related
requir
specimen
sent
refer
laboratori
confirm
outbreak
possibl
requir
day
week
rapid
method
determin
related
organ
isol
could
perform
hospit
microbiolog
laboratori
would
improv
outbreak
detect
one
commerci
system
base
analysi
repetit
element
avail
bacteri
strain
type
number
limit
wide
use
public
health
surveil
monitor
infecti
diseas
commun
order
identifi
occurr
trend
measur
identifi
control
prevent
reappear
exampl
includ
identif
resurg
vaccineprevent
diseas
detect
foodborn
ill
outbreak
monitor
emerg
antimicrobialresist
organ
test
support
surveil
activ
may
occur
clinic
laboratori
often
conduct
andor
confirm
public
health
laboratori
cdc
public
health
surveil
test
must
provid
suffici
inform
distinguish
among
strain
serotyp
perhap
identifi
virul
characterist
suscept
antimicrobi
agent
detail
character
clinic
laboratori
may
requir
although
public
health
laboratori
prepar
transit
novel
technolog
current
reli
cultur
organ
support
character
exampl
pulsenet
enabl
detect
foodborn
outbreak
character
dna
fingerprint
use
pulsedfield
gel
electrophoresi
isol
indistinguish
dna
pattern
identifi
thu
link
patient
ultim
sourc
infect
cultureindepend
technolog
becom
predomin
clinic
front
line
strategi
specimen
preserv
partnership
clinic
laboratori
specimen
collect
critic
one
approach
may
ask
develop
new
technolog
propos
public
health
plan
time
submiss
product
approv
wherea
preserv
organismbas
surveil
capabl
import
short
mediumterm
necess
public
health
develop
altern
surveil
strategi
crucial
longterm
goal
molecular
strategi
whole
genom
sequenc
consider
take
signific
bioinformat
capabl
time
build
databas
replac
built
mani
year
use
older
technolog
also
essenti
ensur
laboratori
provid
standard
inform
surveil
purpos
cdc
recent
propos
new
initi
amd
initi
design
improv
genom
sequenc
bioinformat
capabl
import
public
health
surveil
use
new
technolog
diagnost
biodefenserel
pathogen
offer
uniqu
challeng
develop
util
perhap
greatest
impedi
develop
lie
limit
avail
clinic
specimen
typic
requir
part
tradit
regulatori
submiss
process
insuffici
quantiti
appropri
sampl
partial
address
allow
altern
methodolog
use
spike
specimen
mimic
clinic
specimen
expect
encount
paradigm
may
also
prove
valuabl
set
emerg
infecti
diseas
new
assay
must
rapidli
develop
recent
case
novel
middl
east
respiratori
syndrom
coronaviru
merscov
relev
issu
concern
prompt
diagnost
implement
like
requir
mass
casualti
situat
thu
high
throughput
field
portabl
minim
train
oper
interpret
paramount
featur
novel
assay
final
assay
routin
use
develop
standalon
assay
necessari
longterm
storag
continu
replenish
equip
reagent
would
costli
result
develop
adapt
exist
multiplex
platform
routin
use
common
infecti
diseas
like
pursu
provid
robust
capabl
need
aris
current
regul
allow
develop
deploy
diagnost
assay
case
public
health
emerg
emerg
use
author
eua
use
eua
first
real
test
influenza
pandem
cdc
develop
pcr
assay
fda
clear
use
eua
allow
rapid
develop
deploy
assay
detect
strain
public
health
laboratori
follow
develop
number
commerci
assay
also
clear
eua
use
routin
clinic
laboratori
eua
mechan
util
april
cdc
develop
fda
clear
diagnost
test
emerg
influenza
strain
similarli
june
fda
work
cdc
author
assay
merscov
declar
potenti
threat
public
health
end
may
regulatori
hurdl
might
normal
hinder
rapid
develop
overcom
eua
mechan
declar
emerg
declar
potenti
high
risk
emerg
diagnost
implement
util
resourc
limit
andor
constrain
set
present
uniqu
challeng
rel
tradit
secondari
tertiari
care
set
although
sensit
specif
consider
regardless
set
differ
preval
diseas
potenti
larger
differenti
diagnosi
may
render
predict
valu
less
clinic
use
particular
applic
term
signific
resourc
limit
desir
diagnost
assay
requir
littl
power
input
electr
well
minim
technic
skill
train
oper
interpret
test
portabl
high
storag
requir
specimen
reagent
cold
chain
minim
instrument
abl
withstand
temperatur
extrem
power
surg
electr
requir
final
interv
sampl
collect
clinic
decisionmak
result
must
occur
singl
visit
novel
rapid
test
diagnosi
drugresist
tuberculosi
rapid
antigen
test
malaria
novel
rapid
test
earli
diagnosi
leprosi
exampl
emerg
technolog
applic
develop
world
note
resourceconstrain
set
occur
within
develop
countri
underserv
innerc
rural
area
issu
describ
relev
less
develop
environ
attribut
also
appropri
medic
offic
practic
public
health
clinic
field
oper
fact
develop
technolog
suitabl
diagnost
assay
resourcelimit
countri
case
tuberculosi
malaria
may
creat
opportun
novel
applic
countri
abund
resourc
diagnosi
sever
infect
immunocompromis
patient
also
present
uniqu
diagnost
challeng
immunosuppress
patient
may
minim
atyp
sign
infect
invas
test
may
possibl
due
coagulopathi
sever
ill
minim
invas
approach
predic
host
respons
infect
howev
unlik
effect
face
neutropenia
andor
immunosuppress
therapi
addit
breadth
potenti
pathogen
affect
immunocompromis
greatli
exce
patient
popul
creation
diagnost
panel
target
even
broader
rang
organ
requir
optim
patient
care
diagnos
invas
fungal
infect
particularli
problemat
due
insensit
classic
cultur
microscopi
combin
moder
predict
valu
current
fungal
biomark
diagnost
uncertainti
unnecessarili
delay
initi
appropri
antifung
therapi
turn
link
poor
outcom
varieti
invas
fungal
infect
differ
amplificationbas
strategi
evalu
diagnosi
invas
candida
aspergillu
infect
highrisk
hematolog
patient
vari
result
recent
metaanalys
highlight
lack
assay
standard
combin
inconsist
test
algorithm
sourc
heterogen
across
studi
new
option
diagnosi
varieti
emerg
fungal
diseas
addit
candida
aspergillu
urgent
need
test
develop
pair
robust
laboratori
standard
effort
akin
european
aspergillu
pcr
initi
pediatr
patient
seen
clinic
set
previous
discuss
gener
diagnost
need
similar
howev
pediatr
patient
sever
uniqu
need
specif
address
overarch
unmet
need
valid
test
within
pediatr
popul
due
enhanc
cost
associ
obtain
fda
clearanc
approv
new
diagnost
product
specif
larg
number
children
variou
age
group
need
enrol
difficulti
obtain
inform
consent
inabl
get
adequ
amount
specimen
diagnost
vet
adult
patient
result
assum
similar
children
alway
true
exampl
biomarkerbas
test
pct
need
specif
refer
rang
young
infant
pathogenbas
test
also
need
take
account
colon
rate
children
true
urinari
antigen
test
pneumococc
diseas
test
poor
posit
predict
valu
children
due
high
pneumococc
colon
rate
final
c
difficil
test
question
util
children
year
age
asymptomat
carriag
toxigen
strain
common
addit
need
uniqu
pediatr
includ
need
smaller
sampl
volum
blood
volum
requir
test
often
obtain
safe
young
prematur
infant
term
newborn
approxim
ml
total
blood
volum
prematur
infant
significantli
less
test
valid
less
invas
clinic
sampl
also
desir
although
exclus
pediatr
invas
procedur
difficult
perform
children
reluct
put
children
invas
test
last
pediatr
almost
alway
smaller
diagnost
market
adult
test
often
littl
incent
test
valid
children
therapeut
addit
incent
provid
pediatr
diagnost
valid
fda
clearanc
new
test
methodolog
introduc
clinic
laboratori
particularli
assay
timeli
essenti
chang
clinic
practic
import
hurdl
address
quickli
commun
rapid
result
appropri
care
provid
appropri
public
health
author
studi
investig
util
rapid
test
identifi
mrsa
versu
methicillinsuscept
aureu
mssa
coagulaseneg
staphylococci
posit
blood
cultur
improv
antibiot
manag
mortal
conting
upon
rapid
result
commun
directli
treat
physician
designe
infecti
pharmacist
member
antibiot
stewardship
team
given
financi
constraint
staf
limit
face
mani
laboratori
essenti
effici
mean
commun
develop
involv
manual
phone
call
commun
intermediari
pharmacist
infecti
diseas
consult
antibiot
stewardship
team
may
ideal
guidanc
appropri
therapi
infect
control
measur
also
provid
casebycas
basi
inform
technolog
servic
deliveri
result
mobil
devic
also
requir
provid
electron
commun
support
effect
prefer
autom
transmiss
laboratori
result
benefit
rapid
test
fulli
realiz
although
major
test
infecti
diseas
laboratori
base
poc
rapid
antigenbas
test
wide
use
howev
fdaapprov
rapid
antigen
test
avail
select
pathogen
eg
adenoviru
rotaviru
influenza
influenza
b
rsv
l
pneumophila
serotyp
pneumonia
pyogen
plasmodium
speci
c
difficil
cryptosporidium
giardia
cryptococcu
neoforman
h
capsulatum
fungi
perform
devic
rang
good
eg
sensit
rsv
children
year
age
poor
eg
sensit
influenza
b
geriatr
patient
result
depend
analyt
sensit
test
type
sampl
collect
age
patient
time
test
onset
clinic
symptom
clinician
alway
awar
perform
limit
test
clinic
indic
need
perform
addit
test
result
reduc
sensit
specif
limit
number
analyt
detect
current
evolut
replac
rapid
antigen
poc
test
commerci
platform
perform
realtim
amplif
detect
assay
numer
pathogen
singlestep
cartridgebas
molecular
test
devic
target
pathogen
pertin
clinic
syndrom
eg
respiratori
tract
infect
cn
infect
gastroenter
sepsi
assay
perform
ondemand
requir
minim
handson
time
minut
requir
minim
technic
skill
oper
provid
rapid
result
minut
hour
howev
limit
cartridgebas
platform
throughput
capabl
system
allow
test
perform
time
often
requir
multipl
expens
separ
platform
addit
modul
fda
cliawaiv
molecular
poc
bedsid
test
selfcontain
multiplex
amplif
platform
locat
centralreferr
clinic
laboratori
rapid
respons
laboratori
cliacertifi
minilaboratori
clinic
public
health
facil
still
provid
result
within
need
time
frame
ideal
futur
poc
test
design
test
perform
portabl
handheld
recharg
batteri
oper
rapid
cycl
devic
except
test
detect
chlamydia
trachomati
n
gonorrhoea
major
older
molecular
diagnost
assay
develop
singleanalyt
test
today
molecular
diagnost
test
move
toward
broad
syndrom
screen
approach
trend
result
sophist
technolog
enabl
detect
analyt
time
testsdevic
vari
low
multiplex
analyt
differ
analyt
often
combin
mixtur
pathogen
type
eg
bacteria
virus
parasit
also
antibiot
resist
marker
new
highli
multiplex
cartridgebas
system
detect
major
bacteri
pathogen
caus
commun
ventilatorassoci
hospitalacquir
pneumonia
within
hour
addit
system
detect
antibiot
resist
genet
marker
intent
replac
cultur
addit
character
isol
still
need
perform
cultur
sampl
provid
poc
earli
diagnosi
lead
focus
appropri
antimicrobi
therapi
multiplex
panel
focu
pathogen
found
patient
clinic
pictur
septic
shock
diarrhea
caus
gastrointestin
pathogen
multiplex
enter
diseas
panel
target
common
bacteri
pathogen
salmonella
shigella
yersinia
vibrio
campylobact
speci
addit
bacteri
toxin
eg
shiga
toxin
parasit
eg
giardia
virus
eg
noroviru
select
assay
analyt
must
clinic
relev
analyt
alway
better
test
expens
may
reimburs
least
near
term
multiplex
amplif
platform
replac
activ
viral
cultur
supplement
test
antibiot
vitro
suscept
test
molecular
platform
need
adapt
quickli
chang
clinic
environ
new
pathogen
identifi
eg
merscov
variant
old
pathogen
emerg
eg
influenza
new
antibiot
resist
mechan
evolv
eg
k
pneumonia
carbapenemas
new
delhi
henc
strong
indic
flexibl
test
instrument
design
exampl
multiplex
system
involv
complex
primer
probe
interact
initi
subsequ
amplif
detect
step
addit
new
primer
probe
detect
addit
target
requir
valid
newli
ad
target
demonstr
perform
exist
target
affect
revalid
exist
target
need
undertaken
experiment
evid
requir
demonstr
perform
limit
key
point
address
inhous
studi
furthermor
fda
encourag
assay
develop
archiv
specimen
use
clinic
evalu
futur
use
especi
case
multiplex
panel
expand
idea
appli
exist
clear
multiplex
devic
address
detect
emerg
evolv
pathogen
howev
import
note
mechan
use
inflat
assay
menu
devic
increas
market
rather
use
address
true
public
health
need
test
presenc
nucleic
acid
target
clinic
sampl
necessari
extract
nucleic
acid
pathogen
amplifi
genet
target
detect
amplifi
sequenc
tradit
labor
intens
nucleic
acid
isol
purif
method
replac
autom
platform
incorpor
directli
cartridgebas
devic
nucleic
acid
amplif
technolog
evolv
tradit
realtim
pcr
newer
method
loopmedi
amplif
lamp
transcriptionmedi
amplif
nucleic
acid
sequencebas
amplif
nasba
strand
displac
amplif
sda
technolog
lamp
nasba
sda
isotherm
requir
expens
thermocycl
realtim
nucleic
acid
detect
method
reli
fluorometr
probe
mani
varieti
eg
molecular
beacon
fluoresc
energi
transfer
taqman
scorpion
lock
nucleic
acid
amplifi
target
detect
turbid
chemiluminesc
either
solidbas
liquid
beadbas
microarray
lieu
target
amplif
nucleic
acid
detect
directli
use
sensit
signal
amplif
method
branch
dna
probe
amplif
method
electrospray
ioniz
timeofflight
esitof
mass
spectroscopi
nucleic
acid
isol
clinic
sampl
amplifi
broadrang
primer
target
highli
conserv
genom
region
flank
sequenc
variabl
genet
content
amplifi
nucleic
acid
fragment
enter
ioniz
chamber
esitof
mass
spectromet
charg
strand
leav
electrospray
phase
puls
high
vacuum
nucleic
acid
strand
move
flight
tube
lower
mass
amplicon
travel
faster
reach
detector
higher
mass
amplicon
time
amplicon
detect
mass
spectrum
increas
gener
esitof
interrog
amplicon
weight
determin
base
composit
complementari
dna
strand
multipl
sequenc
small
number
possibl
base
composit
consist
measur
mass
base
composit
forward
revers
amplicon
strand
must
complementari
reduc
possibl
singl
uniqu
base
composit
allow
accur
identif
target
technolog
use
identifi
viral
respiratori
biothreat
pathogen
includ
novel
variant
influenza
resist
gene
specif
toxin
also
detect
major
benefit
abil
identifi
mani
divers
pathogen
without
target
analyt
specif
mass
spectrometri
system
scope
pathogen
detect
depend
accuraci
esitof
databas
although
technolog
great
promis
sever
drawback
current
instrument
process
slow
labor
intens
direct
sampl
test
would
requir
nucleic
acid
isol
amplif
produc
suffici
concentr
nucleic
acid
detect
current
platform
larg
costli
practic
clinic
laboratori
futur
system
need
enhanc
sensit
allow
direct
detect
pathogen
clinic
sampl
new
instrument
significantli
reduc
size
cost
complex
mani
year
naat
combin
tradit
capillari
electrophoresi
sequenc
pyrosequenc
applic
sequenc
use
pathogen
identif
isol
directli
clinic
specimen
freshfrozen
paraffinembed
tissu
sequenc
establish
microbi
etiolog
case
pathogen
identifi
tradit
cultur
method
due
previou
antimicrobi
therapi
eg
cultureneg
endocard
sequenc
provid
genu
identif
gener
strain
specieslevel
identif
isol
test
isol
either
misidentifi
due
high
sequenc
similar
pathogen
eg
n
gonorrhoea
neisseria
meningitidi
use
rna
sequenc
never
identifi
concern
includ
incorrect
sequenc
present
public
databas
high
cost
access
commerci
avail
vet
databas
sequenc
also
use
identifi
known
novel
mutat
relat
drug
resist
due
complex
cost
approach
gener
restrict
larg
univers
laboratori
refer
laboratori
fuel
human
genom
project
market
incent
xprize
nextgener
sequenc
ng
system
develop
demonstr
better
perform
longer
read
length
increas
accuraci
util
applic
requir
fewer
consum
less
laborintens
tradit
sequenc
method
convers
ng
requir
extens
bioinformat
data
interpret
meet
need
routin
clinic
test
compact
ng
system
develop
small
footprint
fast
turnaround
time
use
system
sequenc
could
replac
complex
multifacet
tradit
microbiolog
identif
procedur
biochem
test
sequenc
could
detect
virul
determin
genet
marker
antimicrobi
resist
sequenc
howev
may
miss
new
uncharacter
genet
element
respons
phenotyp
resist
mechan
requir
compani
perform
extens
phenotypicgenotyp
comparison
may
addit
requir
gene
express
analysi
detect
complex
phenotyp
eg
chang
porin
express
relat
carbapenem
resist
sequenc
data
alreadi
prove
valu
track
outbreak
infect
due
resist
bacteria
eg
nih
outbreak
multidrugresist
gramneg
bacteria
cholera
outbreak
haiti
futur
studi
need
address
clinic
relev
find
fragment
nucleic
acid
may
correl
patient
clinic
syndrom
final
ng
system
need
easi
concis
lowcost
data
manag
interpret
softwar
access
wellvet
databas
ng
system
becom
primari
diagnost
approach
infecti
diseas
develop
implement
standard
method
allow
data
share
across
institut
critic
success
ng
public
health
tool
outbreak
detect
respons
surveil
matrixassist
laser
desorptionion
timeofflight
mass
spectrometri
malditof
ms
use
mani
applic
biochemistri
polym
chemistri
proteom
new
malditof
ms
platform
use
routin
clinic
microbiolog
laboratori
rapid
identif
bacteria
fungi
mycobacteria
parasit
malditof
ms
test
rel
simpl
bacteria
requir
transfer
portion
isol
coloni
onto
well
design
dispos
reusabl
target
slide
organ
mycobacteria
fungi
usual
requir
addit
pretreat
step
ensur
nonviabl
organ
manipul
extract
protein
interest
inocul
well
cover
chemic
matrix
gener
acid
dri
target
plate
load
instrument
vacuum
appli
chamber
target
slide
well
puls
laser
convert
sampl
ionic
ga
compos
small
molecul
peptid
small
protein
ioniz
chamber
posit
charg
molecul
acceler
electr
field
enter
timeofflight
mass
analyz
smaller
particl
travel
faster
tube
particl
detector
particl
detector
measur
flight
time
convert
massveloc
valu
plot
mass
spectrogram
spectrogram
compar
valid
librari
spectrogram
use
proprietari
algorithm
specif
manufactur
test
calibr
control
ensur
appropri
perform
malditof
ms
time
first
result
approxim
minut
new
subsequ
result
avail
within
minut
malditof
ms
system
essenti
characterist
success
rapid
accur
result
minim
technic
time
simpl
sampl
prepar
system
also
amen
integr
autom
platform
inocul
malditof
ms
slide
collat
malditof
ms
identif
antimicrobi
suscept
data
initi
cost
malditof
ms
unit
rang
approxim
yearli
mainten
cost
roughli
year
howev
expens
offset
low
reagent
cost
per
identif
compar
tradit
microbiolog
system
approxim
per
identif
plu
save
technic
time
minut
per
identif
clinic
benefit
provid
organ
identif
minut
current
blood
cultur
flag
posit
organ
growth
laboratori
gener
report
result
gram
stain
need
addit
hour
organ
identif
suscept
test
result
altern
technolog
peptid
nucleic
acid
fluoresc
situ
hybrid
naat
system
provid
identif
organ
suscept
data
within
hour
howev
test
current
limit
number
pathogen
detect
cost
per
test
averag
method
technic
time
requir
perform
test
malditof
ms
direct
identif
virtual
organ
posit
blood
cultur
broth
possibl
within
minut
cost
cent
rapid
pathogen
identif
major
impact
select
antimicrobi
therapi
preliminari
studi
demonstr
malditof
ms
also
detect
certain
type
antibiot
resist
mechan
result
structur
modif
antibiot
exampl
hydrolysi
drug
bacteri
lactamas
enzym
detect
due
mass
shift
size
origin
compound
upon
hydrolysi
shift
occur
within
hour
exposur
drug
organ
interest
resist
detect
applic
malditof
ms
earli
stage
develop
ultim
goal
coupl
rapid
suscept
test
malditof
ms
identif
within
hour
receipt
laboratori
recent
new
technolog
combin
pcr
magnet
reson
demonstr
candida
speci
detect
directli
littl
ml
whole
blood
sensit
rang
colonyform
unitsml
technolog
may
overcom
major
limit
current
detect
assay
perform
blood
cultur
bottl
flag
posit
therebi
reduc
detect
time
day
hour
biosensor
analyt
devic
compris
element
physic
proxim
biolog
recognit
element
abl
interact
specif
target
eg
nucleic
acid
protein
pathogen
transduc
abl
convert
recognit
pathogen
measur
signal
biolog
recognit
element
may
natur
occur
eg
microorgan
enzym
antibodi
antigen
nucleic
acid
sequenc
cell
receptor
biolog
deriv
materi
eg
recombin
antibodi
antigen
aptam
engin
protein
biomim
eg
synthet
catalyst
combinatori
ligand
imprint
polym
physic
transduc
optic
electrochem
thermometr
piezoelectr
magnet
micromechan
interact
gener
signal
electrochem
optic
acoust
mechan
calorimetr
electron
amplifi
proport
concentr
target
analyt
success
poc
biosensor
diagnost
devic
need
combin
miniatur
use
exampl
microfluid
simpl
isotherm
amplif
technolog
lamp
robust
sens
techniqu
preliminari
feasibl
studi
demonstr
integr
nucleic
acid
protein
detect
electrochem
biosensor
array
use
detect
monomicrobi
polymicrobi
urinari
tract
infect
electrochemicalbas
sens
techniqu
provid
suffici
select
sensit
lowcost
detect
nucleic
acid
sequenc
amplifi
urin
complement
bacteri
identif
direct
biosensor
quantif
bacteri
rna
develop
monitor
bacteri
growth
antibiot
suscept
test
addit
differenti
imped
use
direct
detect
bacteri
stress
respons
contamin
platelet
sampl
lowcost
power
requir
compat
differ
matric
eas
use
interpret
essenti
clinic
applic
ideal
biosensor
would
abl
detect
target
interest
without
amplif
step
would
requir
mean
enhanc
captur
target
nucleic
acid
andor
protein
suffici
effici
direct
detect
altern
combin
direct
nucleic
acid
protein
captur
pathogen
biomark
might
potenti
achiev
goal
essenti
poc
biosensor
properti
proven
relev
thing
plant
diseas
manag
highli
applic
earli
detect
identif
quantif
human
infecti
agent
detect
patient
colon
certain
pathogen
allow
initi
earli
treatment
infect
control
strategi
signific
outbreak
occur
sensit
timeli
cultur
result
influenc
mani
factor
especi
hospit
patient
previous
administ
andor
concurr
antimicrobi
treatment
technolog
introduc
signific
challeng
face
interpret
data
among
approach
reli
upon
detect
nucleic
acid
directli
clinic
sampl
sometim
uncertainti
regard
clinic
signific
result
nucleic
acid
detect
may
nonviabl
organ
commens
nonpathogen
colon
bacteria
virus
noncontributori
diseas
therefor
nucleic
assay
must
provid
clinic
relev
level
sensit
suffici
scope
detect
relev
pathogen
case
mani
virus
genotyp
incorrect
diagnosi
base
presenc
absenc
nucleic
acid
could
actual
obscur
determin
real
pathogen
clinic
studi
evalu
presenc
respiratori
virus
asymptomat
patient
indic
old
doctrin
consid
presenc
respiratori
viru
clinic
signific
longer
true
individu
shed
respiratori
viru
without
evid
diseas
eg
adenoviru
addit
clinic
signific
mix
viral
infect
alway
clear
eg
bocaviru
part
mix
viral
infect
instanc
clinician
face
challeng
ask
colon
versu
infect
pathogen
respons
diseas
distinguish
colon
contamin
true
pathogen
interpret
test
result
close
collabor
laboratori
critic
includ
adher
specimen
collect
transport
guidelin
understand
test
perform
pretest
probabl
diseas
relianc
clinic
judgment
includ
consult
infecti
diseas
physician
exampl
diagnosi
bloodstream
infect
detect
nucleic
acid
coagulaseneg
staphylococcu
speci
blood
person
prosthet
valv
possibl
endocard
differ
detect
immunocompet
communityacquir
pneumonia
aureu
meca
gene
nucleic
acid
detect
febril
patient
appropri
risk
factor
diagnosi
mrsa
bacteremia
clear
answer
straightforward
cmv
viremia
detect
patient
fever
icu
whose
blood
cultur
neg
bacteria
lastli
detect
antibiot
resist
gene
directli
clinic
sampl
challeng
mere
presenc
may
alway
correl
gene
express
clinic
resist
therapi
addit
linkag
resist
marker
specif
organ
necessari
determin
relev
posit
result
exampl
detect
meca
gene
skin
infect
necessarili
mean
patient
mrsa
major
nonpathogen
coagulaseneg
staphylococcu
speci
colon
skin
also
contain
meca
gene
detect
vanb
gene
rectal
swab
necessarili
indic
patient
colon
vancomycinresist
enterococcu
speci
anaerob
part
normal
stool
flora
contain
vanb
gene
despit
limit
molecular
method
reli
nucleic
acid
amplif
offer
uniqu
advantag
detect
pathogen
specimen
collect
initi
antimicrobi
treatment
henc
opportun
deescal
empir
therapi
increas
specif
antimicrobi
therapi
furthermor
disappear
pathogen
nucleic
acid
suggest
organ
erad
might
justifi
shorter
cours
treatment
last
novel
molecular
technolog
may
lead
new
insight
diseas
pathogenesi
reveal
previous
unknown
inform
inform
gener
sequenc
mass
spectrometri
complex
test
bring
challeng
sequenc
exampl
provid
signific
amount
data
data
interpret
part
data
import
data
relat
infecti
organ
detect
need
studi
clarif
genotyp
data
relat
phenotyp
data
may
also
unknown
complex
test
may
requir
complex
data
analysi
algorithm
analysi
incomplet
data
wholegenom
sequenc
array
technolog
consist
data
receiv
older
technolog
exampl
wherea
previous
test
result
may
simpli
report
reactiv
advanc
technolog
provid
much
inform
turn
necessit
decis
data
interpret
prioriti
report
format
link
laboratori
equip
laboratori
inform
manag
system
must
design
result
clearli
present
easili
understood
clinician
concept
phase
potenti
new
diagnost
product
inform
collect
healthcar
institut
scientif
advisori
board
market
data
potenti
market
product
estim
research
develop
cost
anticip
cost
clinic
trial
regulatori
requir
calcul
potenti
return
invest
determin
return
invest
favor
project
proce
concept
phase
number
target
organ
new
diagnost
product
may
vari
dozen
depend
intend
use
product
addit
target
increas
cost
assay
increment
input
laboratori
director
clinician
critic
balanc
clinic
need
versu
cost
efficaci
recent
chang
ethic
guidelin
conflict
interest
rule
mani
academ
center
healthcar
system
make
difficult
key
opinion
leader
specif
expertis
infecti
diseas
particip
compani
advisori
board
expert
panel
servic
forbidden
even
consult
serv
hisher
time
without
compens
thu
difficult
industri
gaug
unmet
need
laboratori
ultim
bedsid
although
appropri
avoid
conflict
interest
loss
access
key
expert
detriment
product
design
develop
next
phase
technic
feasibl
progress
function
multipl
factor
includ
creativ
avail
materi
freedom
oper
creativ
short
suppli
intellectu
properti
ip
freedom
oper
ie
absenc
ip
barrier
limit
direct
project
may
take
explor
ip
issu
beyond
scope
paper
note
ip
major
barrier
product
develop
compani
option
licens
technolog
own
other
high
cost
royalti
licens
fee
particularli
infecti
diseas
target
cost
prohibit
next
step
beta
trial
test
method
valid
conflict
interest
rule
impact
abil
compani
get
independ
valid
novel
test
method
realworld
laboratori
set
even
clinic
trial
evalu
new
product
auspic
institut
review
board
irb
may
consid
conflict
interest
laboratori
compens
work
provid
laboratori
expert
becom
inaccess
compani
forc
engag
laboratori
lack
specif
expertis
eg
viral
cultur
extract
rna
clinic
sampl
need
evalu
new
product
must
provid
addit
train
find
develop
necessari
number
laboratori
appropri
expertis
process
larg
number
sampl
need
clinic
trial
costli
challeng
even
sampl
sent
central
laboratori
case
feasibl
one
recent
studi
sampl
either
lost
destroy
shipment
central
laboratori
mani
clinic
microbiolog
laboratori
research
technologist
whose
job
overse
clinic
trial
new
diagnost
test
method
research
posit
long
elimin
due
financi
constraint
therebi
make
clinic
trial
burden
exist
laboratori
staff
thu
number
microbiolog
laboratori
will
take
part
clinic
trial
new
product
shrunk
last
decad
limit
even
conflict
interest
rule
institut
regul
overhead
cost
exceed
institut
make
contract
place
expens
pursu
identif
appropri
laboratori
compani
must
valid
accuraci
new
diagnost
test
gold
standard
refer
method
often
less
sensit
sometim
consider
instanc
less
specif
new
method
conflict
manag
vari
product
product
stage
compani
like
multipl
interact
fda
result
agreement
refer
method
use
clinic
trial
design
resolut
truth
ie
constitut
true
posit
result
true
neg
result
may
requir
particip
laboratori
run
multipl
commerci
assay
establish
patient
infect
statu
done
evalu
naat
chlamydia
gonorrhea
assay
strategi
success
multipl
product
evalu
also
expens
increasingli
bidirect
sequenc
target
nucleic
acid
organ
directli
clinic
sampl
use
ultim
arbitr
posit
neg
bidirect
sequenc
requir
develop
valid
addit
sequenc
primer
test
protocol
cost
nucleic
acid
sequenc
decreas
dramat
routin
laboratori
use
cost
good
laboratori
practic
certifi
glp
sequenc
reput
laboratori
phred
score
sequenc
data
almost
doubl
last
year
cost
nucleic
acid
sequenc
analysi
add
cost
clinic
trial
may
prohibit
smaller
compani
anoth
challeng
access
clinic
sampl
contain
rare
encount
pathogen
mani
clinic
laboratori
longer
freez
specimen
contain
novel
unusu
organ
workup
becom
difficult
find
exampl
csf
sampl
contain
agent
viral
bacteri
mening
nasal
wash
novel
respiratori
virus
even
critic
clinic
sampl
avail
cost
access
sampl
mani
case
becom
prohibit
institut
may
strict
irb
polici
regard
provis
sampl
avail
biorepositori
prospect
collect
valid
clinic
sampl
would
directli
address
problem
see
appendix
b
prospect
archiv
sampl
repositori
recommend
recent
report
transatlant
task
forc
antimicrobi
resist
tatfar
center
health
secur
formerli
center
biosecur
univers
pittsburgh
medic
center
hold
potenti
address
challeng
diagnost
develop
howev
challeng
success
implement
repositori
acknowledg
tatfar
includ
expens
difficulti
anticip
exactli
type
specimen
collect
inform
consent
key
issu
cost
maintain
thousand
sampl
may
may
use
may
may
appropri
specimen
given
assay
develop
variabl
sampl
collect
store
critic
factor
import
develop
standard
protocol
collect
storag
consult
regul
exampl
current
infecti
diseas
biorepositori
contract
resourc
niaid
run
aspergillu
technolog
consortium
contain
prospect
collect
archiv
sampl
atrisk
subject
develop
proven
probabl
invas
aspergillosi
repositori
provid
compani
develop
diagnost
aspergillosi
sourc
posit
neg
clinic
sampl
although
thousand
specimen
collect
date
new
diagnost
test
develop
second
approach
ondemand
model
access
prospect
collect
sampl
made
avail
compani
demonstr
product
approach
specimen
collect
requir
new
niaid
vaccin
treatment
evalu
unit
design
facilit
earlystag
develop
drug
vaccin
diagnost
model
may
reduc
risk
associ
develop
new
assay
compani
seek
regulatori
approv
novel
diagnost
product
must
demonstr
redemonstr
clinic
util
product
regulatori
approv
addit
clinic
trial
pma
pathway
new
uniqu
product
expens
k
clearanc
pathway
modif
previous
approv
test
differ
may
exceed
presum
return
invest
product
fortun
primarili
issu
molecular
assay
target
viral
pathogen
hbv
hcv
hpv
cmv
ebv
coronaviru
caus
sever
acut
respiratori
syndrom
sar
unfortun
extend
clinic
trial
may
cost
prohibit
even
though
commerci
viabl
market
even
commerci
wellestablish
pcr
assay
assay
hsv
diagnos
meningoenceph
csf
quit
difficult
current
regulatori
environ
given
pauciti
sampl
avail
lack
predic
devic
need
demonstr
posit
outcom
test
algorithm
follow
fda
approv
clearanc
new
assay
compani
must
abl
manufactur
compon
assay
includ
collect
transport
devic
instrument
reagent
dispos
good
manufactur
practic
consist
depend
fashion
gear
manufactur
facil
largescal
product
assay
challeng
particularli
smaller
compani
often
reli
multipl
manufactur
provid
requisit
compon
assay
furthermor
small
compani
often
underestim
effort
expens
requir
coordin
manufactur
part
kit
product
ship
product
subsequ
technic
support
includ
document
everi
aspect
process
laboratorydevelop
test
ldt
vitro
diagnost
test
develop
valid
use
primarili
inhous
patholog
diagnost
test
intend
use
laboratori
develop
howev
larger
refer
laboratori
offer
test
broadli
commerci
basi
test
current
requir
go
fda
approv
clearanc
pathway
like
commerci
develop
diagnost
test
fda
gener
chosen
exercis
enforc
discret
may
chang
near
futur
analytespecif
reagent
ldt
compon
also
regul
fda
use
ruoiuo
devic
clinic
diagnost
fda
issu
guidanc
recommend
carri
label
signal
use
limit
investig
purpos
manufactur
investig
product
may
legal
distribut
product
commerci
without
fda
premarket
review
long
market
investig
use
mani
ldt
diagnost
molecular
test
avail
commerci
therefor
use
geograph
distant
state
clinic
specimen
obtain
ldt
present
uniqu
regulatori
issu
although
vital
healthcar
concern
highrisk
ldt
assur
provid
clinic
relev
inform
clinician
patient
wherea
mani
laboratori
go
consider
length
valid
assay
prior
make
avail
commerci
develop
inhous
qualiti
assur
program
monitor
perform
qualiti
assur
data
assay
often
readili
avail
accuraci
may
difficult
assess
incumb
upon
laboratori
submit
sampl
test
use
ldt
substanti
accuraci
perform
test
prior
send
sampl
import
need
safeti
efficaci
balanc
need
flexibl
avail
custom
test
local
popul
unit
state
countri
regul
market
vitro
diagnost
product
europ
vitro
diagnost
ceivd
mark
indic
clearanc
use
come
set
regul
requir
clearanc
mani
product
selfdeclar
base
data
file
diagnost
test
sexual
transmit
infect
target
rigor
clearanc
pathway
compani
plan
market
diagnost
product
countri
australia
canada
china
india
japan
mexico
countri
south
central
america
find
addit
regulatori
hurdl
quit
complic
involv
multipl
clinic
trial
run
exclus
countri
permiss
market
sought
although
number
multilater
discuss
among
variou
regulatori
bodi
focus
harmon
regulatori
requir
global
like
sever
year
away
meantim
compani
must
often
undertak
multipl
clinic
trial
set
guidelin
gain
necessari
approv
market
product
multipl
countri
around
world
diagnost
compani
involv
develop
novel
test
infecti
agent
rang
size
employe
thousand
employe
research
develop
budget
rang
thousand
billion
dollar
mani
smaller
compani
seek
fund
varieti
sourc
includ
govern
grant
partnership
ventur
capit
compani
pharmaceut
compani
financ
research
develop
effort
academ
partnership
often
critic
smaller
firm
mani
integr
product
develop
line
research
case
small
compani
evolv
success
academ
program
univers
campus
mani
nih
studi
section
given
diagnost
grant
high
prioriti
sbir
program
partnership
industri
feder
govern
fruit
yield
number
success
product
consider
interest
explor
role
molecular
diagnost
clinic
trial
novel
antimicrobi
agent
potenti
use
rapid
diagnost
test
includ
screen
patient
specif
clinic
syndrom
target
microorgan
prior
concomit
studi
enrol
enrich
studi
popul
patient
less
common
infect
smaller
clinic
trial
patient
enrol
would
proven
microbi
etiolog
ill
companion
diagnost
test
test
drug
link
togeth
part
clinic
trial
ultim
prescrib
evolv
regulatori
guidanc
codevelop
drug
diagnost
current
make
challeng
area
mani
pharmaceut
compani
search
diagnost
partner
whose
assay
implement
make
clinic
trial
cost
effect
preenrich
evalu
patient
exampl
clinic
trial
novel
antimicrobi
agent
activ
mrsa
mssa
skin
skin
structur
infect
may
want
rapid
test
hour
less
screen
wound
specimen
potenti
patient
identifi
specif
mrsa
infect
strategi
usual
goe
smoothli
diagnost
test
alreadi
exist
howev
pharmaceut
compani
may
seek
diagnost
partner
develop
test
singl
pathogen
bodi
site
organ
exampl
lung
multipl
pathogen
may
etiolog
agent
diseas
conflict
begin
emerg
diagnost
compani
want
develop
product
broad
clinic
util
market
ie
one
detect
multipl
infecti
agent
pharmaceut
compani
interest
limit
panel
infecti
agent
often
singl
organ
limit
financi
commit
although
would
appear
would
consider
synergi
pharmaceut
diagnost
compani
could
share
cost
develop
clinic
trial
synergi
far
clinic
condit
requir
antimicrobi
therapi
either
optim
diagnost
assay
avail
poor
diagnost
test
perform
clinic
set
clinic
popul
test
limit
util
patient
manag
mani
fdaapprov
clear
test
ldt
valid
use
ideal
specimen
specif
welldefin
popul
interpret
result
realworld
clinic
practic
eg
patient
may
antibiot
time
diagnost
test
remain
unsatisfactori
widespread
uptak
practition
fact
accept
standard
posit
neg
predict
valu
would
translat
chang
patient
manag
lack
vari
base
diseas
consider
turnaround
time
also
determin
util
uptak
diagnost
test
timesensit
diagnos
requir
immedi
specif
target
therapi
avoid
sequela
diseas
rel
toxic
empir
treatment
test
best
perform
near
patient
either
poc
test
rapid
respons
laboratori
convers
diagnos
diseas
progress
much
slower
rate
turnaround
time
less
urgent
permit
use
test
perform
central
laboratori
anoth
signific
barrier
widespread
uptak
use
mani
diagnost
test
pauciti
clinic
applic
outcom
data
show
use
test
make
treatment
decis
superior
term
morbid
mortal
cost
compar
empir
therapi
outcom
data
clinic
relev
paramet
eg
clinic
outcom
complic
mortal
critic
provid
effect
use
laboratori
assay
consensu
profession
societi
guidelin
influenc
diagnost
test
incorpor
clinic
practic
infecti
diseas
guidelin
alway
explicitli
includ
use
diagnost
test
consensu
guidelin
usual
creat
panel
clinic
expert
evalu
perform
relev
diagnost
assay
base
avail
literatur
well
expert
opinion
howev
often
clinic
microbiolog
expert
use
test
tabl
use
relev
assay
includ
clinic
practic
guidelin
impli
standard
care
well
standard
endors
except
publish
profession
societi
guidelin
recommend
use
diagnost
assay
make
easier
clinician
use
argu
test
cover
reimburs
beyond
guidelin
clinician
educ
key
requir
success
uptak
appropri
use
new
diagnost
test
without
knowledg
clinician
understand
potenti
valu
appropri
use
new
test
wherea
graduat
medic
educ
play
import
role
teach
new
healthcar
provid
use
exist
diagnost
test
continu
educ
program
regular
interact
clinician
clinic
microbiologist
also
vital
facilit
appropri
use
new
test
interpret
result
exampl
recent
challeng
includ
molecular
diagnost
test
viral
respiratori
pathogen
import
appropri
test
practic
c
difficil
test
exclud
form
stool
specimen
avoid
overtreat
colon
recent
chang
develop
rapid
molecular
test
mani
case
outpac
clinician
awar
uptak
laboratorian
facilit
educ
healthcar
personnel
scope
use
diagnost
test
interpret
recommend
repeat
followup
test
exampl
blog
new
assay
updat
specimen
collect
guidelin
present
key
stakehold
infecti
diseas
clinician
serv
critic
liaison
healthcar
provid
clinic
microbiolog
lab
engag
expertis
assist
determin
best
diagnost
test
interpret
laboratori
result
lead
improv
patient
care
limit
resourc
access
may
impact
avail
diagnost
test
resourcelimit
set
around
world
well
rural
resourcelimit
set
unit
state
mani
case
exampl
newli
avail
rapid
molecular
test
cost
high
thu
test
avail
standard
care
may
bill
reimburs
test
new
technolog
may
complex
level
healthcar
complex
test
volum
test
particular
site
sometim
low
ensur
compet
test
laboratori
personnel
howev
may
less
issu
newer
technolog
userfriendli
addit
robust
technolog
breakag
need
mainten
oner
mani
set
technolog
need
specimen
prepar
transport
need
highspe
centrifug
refriger
specimen
transport
inabl
batch
specimen
may
also
affect
feasibl
use
distanc
refer
laboratori
specimen
transport
remain
signific
barrier
resourcelimit
set
although
creativ
approach
transport
use
public
buse
motorbik
text
messag
result
transmiss
sampl
prepar
dri
blood
spot
start
impact
nonetheless
even
opportun
current
exist
effici
specimen
transport
central
lab
sometim
lack
furthermor
remain
variabl
robust
inform
technolog
infrastructur
result
report
includ
interfac
diagnost
instrument
rapid
deliveri
result
via
laboratori
inform
system
electron
health
record
difficulti
concern
regard
reimburs
new
expens
diagnost
test
may
hamper
innov
signific
challeng
widespread
use
technolog
reimburs
unit
state
involv
code
health
servic
condit
determin
payment
coverag
thirdparti
payer
determin
level
payment
code
diagnost
test
develop
cpt
system
maintain
american
medic
associ
ama
intern
classif
diseas
ninth
revis
clinic
soon
implement
patient
diagnos
use
combin
cpt
code
bill
obtain
new
cpt
code
revis
exist
one
accommod
emerg
diagnost
test
complex
often
lengthi
process
take
year
applic
new
cpt
code
must
submit
ama
cpt
editori
panel
accord
specif
schedul
time
per
year
must
support
cpt
advisori
committe
stakehold
furthermor
obtain
coverag
test
may
vari
insur
current
code
payment
mechan
often
reflect
valu
new
diagnost
test
payment
laboratori
test
perform
inpati
depend
type
insur
cover
patient
eg
hmo
manag
care
organ
medicar
medicaid
indemn
selfpay
specif
payment
contract
healthcar
provid
insur
laboratori
test
perform
medicar
inpati
part
diagnosi
relat
group
payment
method
separ
payment
individu
laboratori
test
gener
avail
similar
bundl
payment
mandat
mani
nonmedicar
patient
insur
hospit
contract
outpati
test
cpt
code
medicar
coverag
advisori
committe
advis
cm
regard
diagnost
test
coverag
includ
determin
suffici
evid
well
health
benefit
medicar
pay
outpati
laboratori
test
accord
fee
schedul
howev
medicar
reimburs
decis
made
local
rather
nation
level
coverag
diagnost
test
vari
region
given
lack
standard
determin
coverag
pose
challeng
develop
dissemin
new
diagnost
product
cm
creat
polici
address
inconsist
coverag
test
includ
hepat
hiv
bacteri
urin
cultur
payment
new
diagnost
test
often
assign
crosswalk
cm
decid
new
test
similar
exist
clinic
test
gap
fill
use
local
payment
data
assign
new
test
code
payment
novel
diagnost
challeng
given
cm
may
easili
abl
determin
whether
use
crosswalk
gap
fill
set
reimburs
collect
gap
fill
data
time
consum
therefor
new
test
code
price
assign
use
crosswalk
code
frequent
receiv
lower
payment
rate
complianc
bill
remain
challeng
clinic
laboratori
may
also
limit
avail
test
case
reimburs
cover
cost
test
limit
laboratori
interest
offer
test
may
limit
test
avail
use
clinician
case
charg
may
high
leav
consider
cost
patient
thu
limit
clinician
order
test
routin
reimburs
essenti
nonexist
test
develop
recent
malditof
instrument
databas
avail
research
use
ruo
limit
bill
public
privat
payer
feder
state
level
laboratori
typic
bill
ruo
test
current
guidelin
allow
use
ruo
instrument
reagent
clinic
laboratori
costeffect
anoth
import
consider
use
diagnost
test
decis
maker
healthcar
system
consid
rel
cost
outcom
diagnost
test
hospit
clinician
face
scrutini
cost
therapi
includ
evalu
physicianspecif
manag
cost
clinician
administr
face
decis
determin
test
inde
worth
cost
assess
costeffect
laboratori
test
import
evalu
cost
save
healthcar
system
newer
molecular
test
may
increas
cost
laboratori
lead
decreas
length
stay
reduc
use
antibiot
save
offset
addit
cost
test
unfortun
mani
institut
silo
approach
budget
lead
consid
laboratori
cost
see
novel
test
expens
compar
tradit
method
studi
establish
costeffect
tradit
diagnost
test
rather
limit
widespread
use
molecular
method
led
increas
number
studi
examin
cost
save
associ
test
molecular
test
increas
sensit
compar
eia
led
better
detect
c
trachomati
infect
women
result
reduct
complic
pelvic
inflammatori
diseas
ectop
pregnanc
overal
cost
save
even
though
cost
molecular
test
significantli
higher
cost
eia
find
follow
studi
assess
clinic
impact
rtpcr
detect
enteroviru
csf
pediatr
patient
asept
mening
multipl
studi
shown
reduct
antibiot
use
hospit
cost
ancillari
test
andor
length
hospit
stay
enteroviru
test
perform
within
hour
specimen
collect
histor
control
studi
illustr
import
ensur
clinic
respons
rapid
test
rapid
hour
pcr
assay
aureu
mrsa
perform
blood
cultur
gram
stain
result
show
gramposit
cocci
cluster
result
immedi
page
respons
physician
infecti
diseas
pharmacist
compar
control
time
period
avail
pcr
mean
time
switch
empir
vancomycin
either
nafcillin
cefazolin
mssa
bacteremia
decreas
day
implement
aureu
pcr
test
mean
length
hospit
stay
decreas
day
mean
per
patient
hospit
cost
decreas
contrast
anoth
studi
similar
design
fail
show
reduct
time
optim
antibiot
therapi
benefit
achiev
due
failur
facilit
action
part
physician
provid
similar
first
studi
rapid
detect
candida
speci
directli
posit
blood
cultur
rapid
report
healthcar
provid
pharmacist
allow
target
use
antifung
therapi
result
reduct
use
echinocandin
therapi
overal
cost
save
malditof
ms
instrument
recent
avail
use
clinic
microbiolog
laboratori
sever
studi
shown
incorpor
use
malditof
ms
identif
bacteria
yeast
provid
result
sever
day
earlier
compar
standard
identif
method
substanti
reduct
reagent
labor
cost
combin
antimicrobi
stewardship
intervent
malditof
ms
reduc
unnecessari
day
antibiot
treatment
work
need
done
assess
costeffect
diagnost
test
avail
rapid
test
increas
imper
determin
test
impact
clinic
decis
meaning
way
success
diagnost
test
requir
addit
accur
clinic
relev
test
perform
time
manner
rapid
commun
result
team
provid
care
patient
laboratori
embrac
new
technolog
clia
verif
accuraci
perform
requir
process
follow
simpler
pathway
qualit
assay
quantit
assay
yet
exact
requir
success
verif
commerci
product
elus
number
profession
societi
weigh
constitut
accept
verif
valid
studi
guidelin
often
conflict
verif
studi
difficult
organ
preval
rare
pathogen
diseas
find
clinic
materi
may
difficult
addit
often
laboratori
face
request
test
matrix
assay
fda
indic
yet
may
common
specimen
receiv
laboratori
diagnosi
infect
exampl
given
variabl
sampl
obtain
bronchoscopi
diagnost
compani
may
includ
specimen
among
approv
sourc
respiratori
viru
detect
submit
applic
fda
yet
may
best
specimen
sickest
patient
certain
syndrom
either
laboratori
offer
test
report
specif
analyt
altern
sampl
type
must
go
great
expens
effort
valid
specimen
type
verif
multiplex
panel
laboratori
may
need
find
enough
specimen
contain
differ
pathogen
depend
upon
assay
requir
tremend
resourc
significantli
delay
assay
implement
laboratori
face
dilemma
target
panel
novel
viru
respiratori
panel
yet
verifi
becom
posit
laboratori
instanc
hotli
debat
depend
mani
instanc
clinic
social
public
health
impact
correct
incorrect
result
eg
report
falseposit
test
influenza
altern
sampl
type
either
laboratori
offer
test
report
specif
analyt
must
go
great
expens
effort
valid
analyt
moreov
verificationvalid
rare
analyt
materi
may
even
avail
studi
anoth
challeng
implement
newer
assay
often
new
assay
sensit
exist
refer
method
problem
becom
resolv
result
posit
new
method
neg
gold
standard
case
old
gold
standard
eg
c
trachomati
cultur
c
difficil
eia
test
call
question
ideal
laboratori
would
access
clinic
present
patient
part
verif
valid
process
major
barrier
case
obtain
inform
case
fda
clinic
trial
provid
clinic
data
may
requir
obtain
inform
consent
add
expens
trial
addit
mani
laboratori
extens
experi
conduct
fda
trial
may
infrastructur
obtain
consent
therefor
would
abl
particip
access
patient
record
may
possibl
may
facil
distanc
trial
laboratori
institut
barrier
may
exist
laboratori
wish
evalu
new
technolog
clinic
partner
outsid
fda
approv
process
often
find
increasingli
difficult
find
fund
sourc
support
evalu
given
cost
test
lack
reimburs
diagnost
tremend
impact
manag
patient
infecti
diseas
essenti
outbreak
detect
respons
public
health
surveil
transit
convent
cultur
antigen
detect
method
newer
molecular
method
abil
provid
accur
result
clinic
meaning
time
frame
near
point
care
never
greater
diagnos
hsv
enceph
without
molecular
test
manag
patient
without
viral
load
valu
distant
memori
molecular
revolut
past
year
dramat
chang
manag
patient
viral
infect
expand
bacteri
fungal
infect
one
technolog
malditof
ms
pois
complet
chang
identif
bacteri
fungal
pathogen
allow
identif
within
minut
growth
media
yet
despit
extraordinari
technolog
advanc
challeng
remain
fda
approv
clear
molecular
test
avail
remark
limit
number
pathogen
gener
diagnost
notabl
underutil
major
issu
prevent
broad
adopt
diagnost
test
includ
slow
turnaround
time
poor
test
perform
characterist
high
complex
test
easili
adopt
mani
clinic
set
lack
understand
valu
diagnost
limit
access
test
high
cost
clinician
need
access
rapid
simpl
test
rule
infect
diagnos
syndrom
sepsi
pneumonia
identifi
specif
pathogen
resist
determin
test
avail
dramat
improv
patient
care
reduc
healthcar
cost
shown
molecular
test
diagnosi
enterovir
mening
test
meet
standard
desper
need
polici
paper
idsa
review
current
state
diagnost
unmet
clinic
need
assess
new
technolog
could
address
need
investig
barrier
develop
adopt
new
diagnost
broad
rang
recommend
provid
address
identifi
challeng
tabl
need
comprehens
commit
develop
technolog
allow
test
move
highli
complex
laboratori
laboratori
bedsid
creat
program
educ
clinician
proper
use
interpret
test
invest
costeffect
clinic
outcom
studi
advanc
inform
system
allow
rapid
commun
test
result
healthcar
provid
public
health
agenc
also
rapid
action
respons
test
result
import
consid
public
health
implic
innov
develop
ensur
unintend
neg
effect
capac
identifi
respond
track
infecti
public
health
threat
progress
requir
engag
coordin
number
stakehold
includ
fund
agenc
regulatori
agenc
public
health
agenc
diagnost
compani
healthcar
system
clinic
microbiolog
laboratori
profession
clinician
profession
societi
congress
must
play
role
increas
fund
diagnost
research
enact
legisl
address
identifi
challeng
success
implement
recommend
requir
commit
stakehold
open
door
remark
progress
field
diagnost
result
impact
mani
infecti
diseas
technolog
advanc
critic
window
time
har
direct
develop
new
diagnost
benefit
patient
goal
creat
test
develop
rapid
reliabl
accur
simpl
test
reduc
time
diagnosi
truli
improv
qualiti
care
patient
outcom
reduc
healthcar
cost
